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Objective: Cryopreserved valved homograft has become the conduit of choice for
right ventricular outflow tract reconstruction in pediatric cardiac surgery. Aortic
homografts have been frequently used in pulmonary position, but accelerated aortic
homograft fibrocalcification may occur. Blood group incompatibility between re-
ceiver and homograft donor may play a central role in this context.
Methods: Between 1993 and 2000, 59 children (mean age 6.4  4.4 years) received
cryopreserved valved homografts for right ventricular outflow tract reconstruction
and were followed from 2 to 10 years clinically, with echocardiography and chest
radiography for detection of development of homograft calcifications. Seventeen
patients were 3 years or younger. Fifty aortic (85%) and 9 pulmonary homografts
were all used in pulmonary position. Thirty-three patients (56%) had the same blood
group (ABO) as the homograft donor (iso group), and 26 were blood group–
incompatible (non-iso group).
Results: No deaths occurred during follow-up. Six patients (10.2%) required ho-
mograft replacement because of severe fibrocalcifications, and another 3 showed
moderate homograft calcifications (5.1%) at last examination. Freedom from mod-
erate to severe homograft calcification at 8 years (Kaplan-Meier) was 95.2% for the
iso group and 72.9% for the non-iso group (P  .0001). Homograft calcifications
occurred within 2 years of implantation in 6/9 patients (67%) in the non-iso group.
Conclusions: Blood group incompatibility between receiver and homograft donor
seems to play an important role in the development of accelerated fibrocalcifications
in cryopreserved homografts, particularly in the very young (3 years old or
younger). Blood group compatibility should therefore be respected to avoid accel-
erated homograft fibrocalcifications.
Valved homografts, introduced in the 1960s,1 have become themost commonly used valved conduit for reconstruction of theright ventricular outflow tract (RVOT).2,3 Advantages of ho-mografts, such as ease of handling and improved hemostasis, havebeen major contributing factors in its widespread use.4 Earlyresults with cryopreserved homografts have been good.5,6 Fre-
quently cryopreserved valved aortic homografts are used in pulmonary position due
to difficulties in obtaining pulmonary homografts, but accelerated aortic homograft
fibrocalcifications have been described.7-9 The reason for this phenomenon is not
entirely understood. It has been suggested that aortic cryopreserved homografts are
more prone to calcifications than pulmonary homografts, possibly due to a higher
content of elastic tissue and calcium in the aortic wall.7 Moreover, early cryopreser-
vation may provide viable endothelial cells and perhaps also viable fibroblasts, thus
contributing to a greater proportion of antigenically active cells, which could lead to
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a more intense host response.10-13 This increased immuno-
genicity of the graft could perhaps be an important contrib-
uting factor for accelerated fibrocalcifications, particularly
in very young patients. This study was undertaken to eval-
uate the impact of blood group incompatibility on cryopre-
served homograft calcification when used for reconstruction
of the RVOT in a pediatric population.
Methods
From June 1993 and December 2000, 59 pediatric patients (32
boys and 27 girls) had cryopreserved valved homografts implanted
for RVOT reconstruction. The mean age was 6.4  4.4 years,
ranging from 1 month to 14 years of age. Seventeen patients (29%)
were 3 years old or younger at the time of surgery. Primary
diagnosis of their congenital lesions is listed in Table 1. Thirty-
eight patients (64%) had undergone at least 1 earlier cardiac
intervention (Table 2). Thirty-three patients (56%) had the same
blood group (ABO) as the homograft donor (iso group), and in 26
cases there was blood group incompatibility (non-iso group). All
patients in the iso group received homografts within their own
blood group. Potentially compatible homografts were not used in
this series. Fifty aortic valved homografts (85%) and 9 pulmonary
homografts were used, all in pulmonary position.
Homograft Procurement and Preparation
Valved cryopreserved homografts were obtained from 2 sources,
the European Homograft Bank (Brussels Military Hospital, Bel-
gium) and CryoLife Inc (Marietta, Ga). The techniques for prep-
aration of antibiotic-sterilized cryopreserved homografts and stor-
age in liquid nitrogen have been described earlier.14
Surgical Technique
Two surgeons performed all operations. The operation was per-
formed through a median sternotomy and standard cardiopulmo-
nary bypass techniques were applied. During moderate hypother-
mia (28°C to 32°C) and following crossclamping, myocardial
protection was ensured by crystalloid cold cardioplegic solution
repeated every 30 minutes. A longitudinal incision was made
through the right ventricle outflow tract and extended up to the
pulmonary bifurcation and then into both pulmonary branches. The
size of the homograft was determined and was always larger than
the minimum acceptable pulmonary annulus diameter as described
by Pacifico and associates.15 The diameter of the homografts in
this series ranged from 13 to 26 mm (mean diameter 20 mm).
Homografts were thawed and trimmed in standard fashion after
intraoperative assessment of the anatomy. A cryopreserved valved
homograft was then inserted between the extended pulmonary
bifurcation and the right ventricle at the level of the crista su-
praventricularis. The distal anastomoses were performed first. In
some patients bovine or autologous pericardium was used to
enlarge the pulmonary arteries or to provide continuity between
the pulmonary arteries. The proximal anastomoses were made to
vertical infundibulotomies. In addition, a patch of bovine or au-
tologous pericardium was inserted as a hood to cover the enlarged
infundibulotomy. No prosthetic material was used. Associated
procedures were ventricular septal defect closure (n  20), atrial
septal defect closure (n  5), patch plasty of pulmonary artery
branches (n  13), closure of patent foramen ovale (n  4),
tricuspid valve repair (n  3), and tricuspid valve replacement
with mitral homograft (n  1).
Follow-up
All surviving patients were examined in the immediate postoper-
ative period and reexamined with serial transthoracic echocardi-
ography and chest radiography every 6 months, until December
2002. The mean follow-up was 48 months, ranging from 26 to 126
months, with a median follow-up of 39 months. Stenosis was
assessed by measurement of peak velocity through the valve with
continuous-wave Doppler technique. Pulmonary regurgitation was
examined by evaluation of regurgitated jet with pulsed color-flow
Doppler.
Statistical Analysis
Data are presented as the mean  standard deviation. Continuous
variables were analyzed with Student t test and categorical vari-
ables using 2 test. Actuarial estimates were calculated using the
Kaplan-Meier method.
Results
There was no hospital mortality and no mortality during
follow-up. During follow-up 9 patients showed moderate to
severe homograft fibrocalcifications generating either a sig-
nificant pulmonary stenosis or valvular dysfunction or a
combination of both. Oversizing the homograft was
achieved in 90% of the patients, with no difference between
the groups. Sex and age distribution was also without group
TABLE 1. Primary diagnosis for 59 pediatric patients
where cryopreserved valved homografts were used for
RVOT reconstruction
Primary diagnosis No.
Tetralogy of Fallot 25
Pulmonary stenosis or atresia 11
Complex transposition 9
Pulmonary atresia and ventricular septal defect 8
Truncus arteriosus 6
Total 59
TABLE 2. Previous cardiac interventions in 38 pediatric
patients receiving cryopreserved valve homografts
Previous surgical procedure No.
Modified Blalock-Taussig shunt 11
Tetralogy of Fallot repair 10
Ventricular septal defect repair 5
RVOT annular patch 4
Rastelli repair 3
Brock operation 2
Waterstone procedure 1
Pulmonary valvotomy 2
Total 38
RVOT, Right ventricular outflow tract.
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difference. Mean gradient right ventricle to pulmonary ar-
tery was 15.5 13.2 mm Hg, ranging from 0 to 49 mm Hg,
at 3 months after homograft implantation. None of the
patients had a gradient greater than 49 mm Hg. Homograft
calcifications occurred more frequently in the non-iso group
(26.9%; 7/26), than in the iso group (6.1%; 2/33; P .051).
Reoperations
Six of the patients with homograft calcifications and valvu-
lar dysfunction (10.2%) required homograft replacements.
Two patients underwent reoperation within the first postop-
erative year and 3 had reoperation during the second year of
homograft implantation. All these 5 patients belonged to the
non-iso group. One patient underwent reoperation 5 years
after the initial homograft implantation and this patient
belonged to the iso group. The overall actuarial freedom
from reoperation was 88.8% at 8 years, with a notable
difference between the iso group (95.2%) and the non-iso
group (80.8%; 70% confidence interval, 91% to 99% and
72% to 89%, respectively; Figure 1).
Moderate fibrocalcifications without valvular dysfunc-
tion was observed in another 3 patients (5.1%), none of
them severe enough to require reoperation. These patients
continue to be under close surveillance. The overall actuar-
ial freedom from moderate to severe fibrocalcifications (also
including reoperations for homograft dysfunction) was
85.5% at 5 years and 85.5% at 8 years, respectively, again
with a remarkable difference between the iso group (95.2%
and 95.2%) and the non-iso group (72.9% and 72.9%; 70%
confidence interval at 8 years, 91% to 99% and 65% to 81%,
respectively; Figure 2).
It should be noted that moderate to severe homograft
calcifications with or without homograft dysfunction were
diagnosed within 2 years of homograft implantation in as
many as 6 of the 9 patients (67%), all in the non-iso group.
Later appearance of homograft fibrocalcifications was
equally distributed between the groups.
Homograft valvular regurgitation was seen in 3 patients
during follow-up. One patient was diagnosed 6 years after
homograft implantation (non-iso group), and 2 patients
were diagnosed 7 years after homograft implantation (1
from each group). The regurgitation was minimal to mod-
erate and reoperation has so far not been necessary.
Overall actuarial freedom from homograft dysfunction
(moderate to severe fibrocalcifications as well as homograft
valve regurgitation) was 83.8% at 5 years and 67.2% at 8
years. When blood group compatibility was respected (iso
group), freedom from homograft dysfunction was 95.2% at
5 years (70% confidence interval, 92% to 98%) and 83.9%
at 8 years (70% confidence interval, 64% to 80%), which
should be compared with 71.8% (70% confidence interval,
67% to 77%) and 53.2%, respectively, if there was blood
Figure 1. Overall actuarial freedom from reoperation in 59 pediatric patients undergoing reconstruction of the right
ventricular outflow tract with cryopreserved homograft and separated into blood group– compatible (n  33) and
blood group–incompatible (n  26) grafts.
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group incompatibility between homograft donor and ho-
mograft recipient (non-iso group; Figure 3).
Impact of Age, Blood Group Incompatibility, and
Homograft Fibrocalcifications
Children 3 years old or younger in this series encountered
fibrocalcifications markedly more frequent than patients
older than 3 years, 29.4% (5/17) versus 9.5% (4/42). Even
though this difference did not reach statistical significance
(P  .059), a clear trend is apparent. All patients who
developed fibrocalcifications in the young age group in the
early period (within 2 years) after homograft implantation
had blood group incompatibility between homograft donor
and recipient (non-iso group; 55.6%, 5/9 patients), and no
fibrocalcifications were observed in the young when blood
group compatibility was observed (iso group). This differ-
ence between iso group and non-iso group was not encoun-
tered in patients older than 3 years (Table 3).
Even with different protocols for homograft harvest and
preparation at the 2 homograft sources, no difference in
outcome was found either within or across ABO compati-
bility (Table 3).
Because of the small number of pulmonary homografts
used in this series, a meaningful comparison between pul-
monary and aortic homografts in RVOT reconstruction
could not be done, even though there was seemingly no
major difference in outcome, as long as blood group com-
patibility when using aortic homografts was observed.
Discussion
Homografts have been used as extracardiac conduit between
the right ventricle and the pulmonary arteries in various
congenital cardiac malformations, such as complex tetral-
ogy of Fallot, truncus arteriosus,16 pulmonary atresia,1 and
transposition of the great arteries with ventricular septal
defect and pulmonary artery stenosis,17 as well as other
forms of congenital cardiac disease.18 However, initial re-
sults after homografts resulted in a high incidence of ho-
mograft calcifications and subsequent graft failure. Changes
in homograft procurement techniques and utilization of
fresh homografts sterilized with antibiotics and preserved
by freezing led to improved results, which sparked a re-
newed interest for the use of homografts in RVOT recon-
struction in children.19 Today the cryopreserved valved
homograft is the most commonly used conduit for RVOT
reconstruction. Excellent patient survival after RVOT re-
construction using cryopreserved homografts has been re-
ported,2,11,20,21 which also was demonstrated in the present
series. However, homograft calcifications and degeneration
still remain a problem, and the underlying cause for this
progressive development of conduit degeneration is still
under discussion. Echocardiography has been shown to be a
Figure 2. Overall actuarial freedom from moderate to severe fibrocalcifications in 59 pediatric patients undergoing
reconstruction of the right ventricular outflow tract with cryopreserved homograft and separated into blood
group– compatible (n  33) and blood group–incompatible (n  26) grafts.
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reliable method of assessing homograft function during
follow-up,6,11 and serial echocardiographic follow-up ex-
aminations for detection of homograft valvular failure was
consequently employed in the present series.
Several factors have been suggested as cause for ho-
mograft calcification and subsequent graft failure. Small
size of the homograft in comparison to the patient’s body
surface area is 1 such factor.11,22,23 Others risk factors for
homograft degeneration, such as young age of the ho-
mograft recipient and the use of Dacron conduit extension,
have been demonstrated.4,5,11 The use of aortic valved ho-
mografts in the RVOT has been suggested to be a risk factor
in some studies2 but not in others.3,6 Although the vast
majority of the patients in our series (85%) received aortic
homografts, good long-term freedom from graft dysfunction
was still obtained, which is consistent with several previous
reports.3,6
Earlier suggestions regarding the practice of oversizing
valves to allow for growth11,15 was strictly observed for all
patients in our series.
The majority of our patients had as primary diagnosis
tetralogy of Fallot and only few with transposition of the
great arteries, which could explain the good results achieved
in our series. This is consistent with data recently reported
by Dearani and associates,24 who showed that the best
results were obtained for patients with diagnosis of tetralogy
of Fallot and the worst results followed surgery for trans-
position of the great arteries. Similar findings have also been
reported by others.2
An additional participating risk factor for homograft
failure is related to the material used as a hood to cover the
enlarged right ventriculotomy, as well as for patch enlarge-
Figure 3. Overall actuarial freedom from homograft dysfunction (including fibrocalcifications and homograft
valvular regurgitation) in 59 pediatric patients undergoing reconstruction of the right ventricular outflow tract with
cryopreserved homograft and separated into blood group– compatible (n 33) and blood group–incompatible (n
26) grafts.
TABLE 3. Cryopreserved valved homograft fibrocalcifica-
tion for RVOT reconstruction in a pediatric population,
separated into 2 age groups (3 years or older and older
than 3 years of age) in relation to blood group compatibility
between homograft donor and recipient (iso group) versus
blood group incompatibility (non-iso group) and impact of
homograft source
Age at implantation
Fibrocalcifications/No. of patients
Iso group,
no. (%)
Non-iso group,
no. (%)
3 years or younger, n  17 0/8 (0.0) 5/9 (55.6)
Homograft source
CryoLife 0/4 (0.0) 2/4 (50.0)
Brussels 0/4 (0.0) 3/5 (60.0)
Older than 3 years, n  42 2/25 (8.0) 2/17 (11.8)
Homograft source
CryoLife 1/12 (8.3) 1/8 (12.5)
Brussels 1/13 (7.7) 1/9 (11.1)
Total, n  59 2/33 (6.1) 7/26 (26.9)
Homograft source
CryoLife 1/16 (6.3) 3/12 (25.0)
Brussels 1/17 (5.9) 4/14 (28.6)
RVOT, Right ventricular outflow tract.
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ment of the pulmonary arteries.2,3,11,25 We consistently use
an autologous or bovine pericardium for these patches,
which may have contributed to the good outcome reported
in our series.
In addition, solid evidence have recently been presented
in the literature that not only nonimmunological factors but
also an immunological response plays a major role in sub-
sequent homograft dysfunction.25 It has been shown that
cryopreservation results in preservation of endothelial cells
and fibroblasts.13,25 Viable endothelial cells and fibroblasts
are thought to provide the strongest antigenicity.13 Baskett
and coworkers11 recently presented data showing that the
length of time the homograft is sterilized before freezing is
an independent risk factor if the time from retrieval to
preservation was shorter than 24 hours. The homografts
used in the present series all had time from retrieval to
preservation of no more than 72 hours.
Accelerated homograft dysfunction in very young pa-
tients has been suggested earlier.2,3 This accelerated ho-
mograft fibrocalcification is not yet fully understood, even
though there is some evidence that it could be the related to
a host immunological response.8,13,25 Both blood group
incompatibility (ABO) and human leukocyte antigens
(HLA) incompatibility are factors involved in the immuno-
logical response that could affect implanted cryopreserved
homografts. Blood group (ABO) incompatibility between
homograft donor and recipient as a possible major risk
factor resulting in an important immunological response has
been debated extensively.10,24,25 Even though several large
series have failed to identify blood group incompatibility as
an independent risk factor,26 Baskett and associates11 in a
recent study have demonstrated that blood group incompat-
ibility indeed was a significant independent predictor of
homograft failure in multivariate analysis. Our data strongly
support the importance of blood group compatibility as an
important risk factor for accelerated homograft fibrocalci-
fication, particularly in the very young patients when cryo-
preserved aortic valved homografts were used for RVOT
reconstruction. A distinct relationship between young age at
homograft implantation and accelerated, early homograft
dysfunction was clearly demonstrated in our data when
there was blood group incompatibility, which is consistent
with data reported by others.2,26
It has been suggested that homograft failure in very
young children may result from immune response or rejec-
tion.6,8,11,25 Hawkins and associates27 have recently shown
that cryopreserved homografts in children induce a marked
response involving both class I and II anti-HLA antibodies.
Interestingly, this immune response occurs very early,
within 3 months of graft implantation.27 Immunosuppres-
sion of the recipient to diminish the immunological re-
sponse has been suggested by some10 but opposed by oth-
ers.28 However, in a recent prospective randomized trial
Shaddy and coworkers29 were not able to show any reduc-
tion in antibody response when azathioprine was adminis-
trated, and immunosuppression therapy is therefore not
presently recommended. Perhaps strict observance of blood
group compatibility between homograft donor and the very
young graft recipient could be one way to diminish the risk
of accelerated homograft fibrocalcifications as suggested by
our data.
Factors contributing to late homograft failure such as
young age at surgery, late immunological response, and
geometric distortion together with small graft size have
been pointed out earlier. Loss of valvular leaflet extensibil-
ity over time has been suggested to result in increasing
valvular regurgitation.30 In a recent study Baskett and as-
sociates11 suggested that long-term homograft dysfunction
might result from decreased graft viability, early immuno-
logical rejection, or a combination of the two in conjunction
with subtle geometric distortion.
Conclusion
Even though homograft immunogenicity has been demon-
strated to be retained despite the attenuation of endothelial
viability, it is apparent that the precise nature of homograft
valve viability and immunogenicity is not yet fully under-
stood. Although immunological factors do not exclusively
explain valved homograft failure, they cannot be ignored as
important factors triggering early and accelerated homograft
failure, particularly in the very young children. Previous
studies as well as data presented in this series have indicated
that early homograft failure is more in keeping with rejec-
tion than the inevitable tissue degeneration seen in later
failures.
In the present series a markedly higher incidence of early
homograft calcification was detected when blood compati-
bility between homograft donor and receiver was not ob-
served, particularly for patients 3 years old or younger.
Accelerated homograft fibrocalcification was clearly more
often encountered in the very young patients compared with
those older than 3 years, but when blood group compatibil-
ity was strictly observed the risk for accelerated homograft
fibrocalcification was notably diminished.
Further studies on how to safely reduce the impact of
immune response in children receiving cryopreserved
valved homografts are needed.
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Discussion
Dr John A. Hawkins (Salt Lake City, Utah). Thank you, Dr
Christenson. I always enjoy papers that challenge my personally
held beliefs, and I would have to say right up front that generally
I have felt that ABO matching probably does not make much
difference, and if I had a preference, I would select a pulmonary
valve over an aortic valve.
You have looked at 1 of the bigger problems that we face today
in congenital cardiac surgery, basically the problem of premature
early valve dysfunction and subsequent explanation of allograft
valves used in the right ventricular outflow tract.
The problem of ABO blood group antigen compatibility and its
exact role in late allograft dysfunction has really been hotly de-
bated, with a few who feel that it does make a difference and
probably plays a central role in late valve deterioration, and then
perhaps even more feel that it probably plays no role in late valve
allograft failure, as compared with other factors, such as young
age, short donor ischemic times, small Z values, and aortic valve
type. Immune factors have been theorized to be important in
allograft degeneration but are difficult to prove as definitive factor
in late deterioration.
The primary message of this paper was that ABO blood group
antigen incompatibility leads to an increased incidence of valved
allograft calcification in children younger than 3 years of age. A
secondary finding was that aortic allografts functioned well and
perhaps these are not as bad as we think. The central question
raised by the study is, Should we be routinely matching ABO-
compatible allografts with our patients to extend and improve the
durability of these valved allografts? The implications of this paper
are that we should, and personally, I’m not quite so sure. I’m not
ready to jump on board yet.
I have several questions. First, the authors report a series of 59
patients who underwent valved allograft implantation: 33 had
ABO-compatible valves and 26 had ABO-incompatible valves.
There were 9 patients who showed evidence of calcification during
a 4-year mean follow-up period, but only 6 patients who required
valved allograft reoperation during this same time period.
My first question has to do with the authors’ emphasis on
calcification rather than valved allograft failure as a primary end
point and the need for reoperation. So my first question is, Does
calcification of a valved allograft really equate with conduit dys-
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function and reoperation, and is there really any difference be-
tween the groups with regard to ABO incompatibility and the need
for reoperation rather than calcification?
My second and third questions are sort of linked and basically
have to do with making statistical inferences with regards to
attributing differences to ABO incompatibility rather than young
age per se. In other words, how many of the 6 reoperations were
in the younger age group as compared with the older age group,
and with such small numbers of adverse events, namely 6 out of
59, can one really attribute any differences to ABO compatibility
rather than simply young age? I don’t really know the statistics for
doing this. And similarly, do the findings necessarily mean that
ABO incompatibility leads to valved allograft calcification, or are
younger patients simply more likely to calcify a valved allograft
than an older patient?
And lastly, can you tell us how these findings from this study
have impacted your own practice?
Dr Christenson. Thank you, Dr Hawkins, for your kind and
challenging remarks. To answer your question, if calcification
necessarily means conduit dysfunction that requires replacement,
our data do not really suggest that this is always the case but the
rather high number of cases with allograft calcification in our
series did eventually lead to conduit or valvular dysfunction re-
quiring reoperation.
But as you may have noted, there are 3 patients with mild to
moderate calcification that as yet have not developed any conduit
dysfunction, and only time can give us the fate of these conduits,
I believe.
Regarding the question of whether reoperations in the younger
age group are due to young age rather than ABO incompatibility,
I wanted to point out that 6 of the reoperations in our series
occurred in the very young patients, younger than 3 years of age,
at the first operation. All of those patients had calcifications and
conduit dysfunction and all of them were in the non-iso group.
None of the young patients with ABO compatibility were
observed to develop during the follow-up calcifications, neither
calcifications nor conduit dysfunction. And this would, to me,
suggest that it’s rather that blood group incompatibility may trig-
ger calcifications than the age of the patient itself. As a conse-
quence of our findings today, we routinely match ABO, particu-
larly in the young patient group.
And finally, I think to respond to the central question, it seems
based on our data that when blood group match is observed, we do
indeed gain conduit and valvular durability, particularly in the
young patient group, which has been reported in the literature as
having a rather high failure rate when this compatibility is not
observed.
I think that perhaps we should rethink a little bit, and if we are
forced to use aortic homografts in the pulmonary position due to
lack of availability of pulmonary homografts, one should think
about having a blood type match.
Dr Richard A. Jonas (Boston, Mass). Can you please clarify
whether you did echoes on all of these patients?
Dr Christenson. Well, the mean gradient was 15 mm Hg.
Dr Jonas. For the whole series?
Dr Christenson. Yes.
Dr Jonas. And was there a significant difference between those
who had calcification and those who had gradients?
Dr Christenson. It didn’t reach significance, but there was a
clear trend.
Dr Carlos J. Troconis (Caracas, Venezuela). In our country,
we don’t have easy access to homografts and the cost is too high.
We have been using xenografts for the past 10 years, using
whatever is available to us, mainly from Brazil or recently from
Shelhigh, Inc.
In reviewing the world literature several years ago, we found
that almost all the homografts by age 4 to 7 years will be calcified
or disrupted. So we started to use the xenograft, and in early
experiences, we used some low doses of Imuran.
My questions are, Do you think that some type of immunosup-
pression will improve the outcomes of the grafts? Also, do you
think that modifications in the cryopreservation or some gene
expression changes will provide more durability in those conduits?
Dr Christenson. Thank you for your question. I do think that
with immunosuppressive therapy in these patients, one has to be
very careful, because that has a lot of negative implications and
risks. A paper described administering immunosuppression, and it
did not change the immunological response much, when you
looked at the HLA antigen. So that question is not really clear to
me, whether one should suggest immunosuppression in these pa-
tients. I think if one can stick to the blood group matching, one has
already gained quite a lot of terrain.
Dr James L. Monro (Southampton, United Kingdom). I en-
joyed that paper, and I think you are right, we should start taking
more notice of the blood groups. I find it difficult enough to get
hold of homografts anyway. It is now going to be even more
difficult.
The point I would like to make is on the method of preparation
of homografts. Everything is cryopreserved these days, and they
may be fresh, and I think that exacerbates the calcification forma-
tion and the degeneration of the valve. But for years I have been
using aortic homografts in a small series of infants with truncus
arteriosus having aortic homografts; we reported about 3 years ago
the mean time to replacement of the homografts was 13 years, and
the longest patient we had was 26 years.
Now, I’m sure it is something to do with the fact that we used
antibiotic sterilization and then just put them in the fridge for up to
10 weeks at 4°C and used them. These were definitely dead valves,
and I think they have done much better than the cryopreserved
valves that we have these days. I wondered if anybody else is still
using that, and whether you think that’s the reason these valves
seem to have done better.
I was very depressed with the figures that John Brown showed
earlier, on how poorly the homografts he was reporting have done.
And if you can’t get a homograft, the Contegra seems a good idea.
But I think the right blood group homograft is still much better.
Dr Jonas. Perhaps that gets to the question as to how well a
SynerGraft should function since it is a dead homograft without
living endothelial cells. Presumably the SynerGraft should func-
tion much better, but I’m not sure that that’s the experience I have
been hearing. I don’t know if anybody would like to comment very
briefly, or if you would like to comment on that.
Dr Christenson. I don’t really . . ..
Dr Jonas. Thank you.
Dr Jashari Ramadan (Brussels, Belgium). I think the majority
of implanting surgeons agree that the antigenic characteristics of
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the homograft are very low because of the effect of cryopreserva-
tion, and that is one of the reasons that the majority of surgeons
today agree that neither immunosuppression nor blood group
matching is necessary.
My question is actually, Don’t you think that the reason for
accelerated calcification of the homograft in your group of patients
is rather lower age and accelerated growth than the blood group
mismatching?
Dr Christenson. Well, of course in relatively small material
like this, it is difficult to draw a firm conclusion on this point. I do
believe, though, that the calcifications, if we look into the conduit
itself, if you have viable cells somewhere in this conduit, it is in the
tube itself rather than on the leaflets of the valve, and that’s why
you see the calcification and retraction. I do believe that we have
active cells still in the homografts.
Dr Antonio F. Corno (Lausanne, Switzerland). Very quick
question. We noted from Dr Carpentier that homografts implanted
at a younger age do calcify much earlier than in older patients
because of the accelerated calcium metabolism, and this is further
accelerated if the surgeon or the intensivist are using general
administration of intravenous calcium in the immediate postoper-
ative care. So the question is, How do you manage the postoper-
ative care in younger patients? Are you using intravenous calcium
or not?
Dr Christenson. No, we are not using it at all.
Dr David B. Ross (Edmonton, Alberta, Canada). Just a com-
ment about Jim Monro’s remark a moment ago, and another
comment about use of reoperation as an insensitive index of
homograft failure. In a paper we reported a few years ago, we
showed that short storage times prior to cryopreservation actually
did influence early failure, but you can’t tease that out by using
reoperation. We had to use very sensitive and reproducible echo-
cardiographic measurements of valve gradients and regurgitation
to ascertain that. We have a paper in press now showing that
HLA-DR mismatch also predicts early failure, if you look care-
fully with echocardiography.
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